MariMed Inc. (OTCMKTS:MRMD - Get Free Report) saw a large growth in short interest during the month of September. As of September 30th, there was short interest totaling 111,300 shares, a growth of 352.4% from the September 15th total of 24,600 shares. Based on an average daily trading volume, of 2,032,100 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily trading volume, of 2,032,100 shares, the days-to-cover ratio is presently 0.1 days.
MariMed Trading Down 2.4%
Shares of MariMed stock traded down $0.00 on Friday, hitting $0.15. The stock had a trading volume of 1,529,929 shares, compared to its average volume of 792,114. The company has a quick ratio of 0.36, a current ratio of 1.12 and a debt-to-equity ratio of 1.25. MariMed has a one year low of $0.07 and a one year high of $0.23. The stock's 50-day simple moving average is $0.14 and its two-hundred day simple moving average is $0.11. The stock has a market cap of $60.35 million, a price-to-earnings ratio of -5.10 and a beta of 2.98.
Wall Street Analysts Forecast Growth
Separately, Zacks Research downgraded shares of MariMed from a "strong-buy" rating to a "hold" rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy".
Get Our Latest Report on MRMD
MariMed Company Profile
(
Get Free Report)
MariMed Inc engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MariMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MariMed wasn't on the list.
While MariMed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.